Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on February 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded down $0.50 during midday trading on Thursday, reaching $21.71. The stock had a trading volume of 1,462,626 shares, compared to its average volume of 2,479,285. The firm’s fifty day simple moving average is $23.08 and its 200-day simple moving average is $28.93. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $42.37. The stock has a market capitalization of $2.10 billion, a P/E ratio of -3.72 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. During the same quarter in the previous year, the firm posted ($1.39) EPS. The company’s revenue was up 25.5% on a year-over-year basis. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the company. Assetmark Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Smartleaf Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the period. Finally, Covestor Ltd grew its holdings in Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. HC Wainwright reduced their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Leerink Partners decreased their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Wedbush reiterated a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Finally, Wells Fargo & Company reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $65.76.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data showed improved control of ammonia levels in patients with a rare inherited disorder — a meaningful clinical proof point that could support future regulatory filings and long‑term revenue upside if translated into approvals and launches. Ultragenyx gene therapy Reuters story
• Neutral Sentiment: JPMorgan cut its price target substantially from $120 to $74 but maintained an “overweight” rating — the new PT still implies a large percentage upside versus the current share price, so the note is a mix of analyst caution on near‑term valuation and continued conviction in longer‑term potential. Benzinga coverage of JPMorgan note
• Neutral Sentiment: Management presentations at recent healthcare conferences (Leerink and Barclays) have been posted as transcripts — useful for investors wanting updated pipeline timelines, commercial strategy and R&D prioritization but not immediate catalysts by themselves. Leerink presentation transcript Barclays presentation transcript
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applicants in securities class actions alleging disclosure/SEC‑related issues; firms issuing notices include Pomerantz, Schall, DJS, Rosen, Faruqi and others — the repeated filings and reminders (lead‑plaintiff deadline April 6, 2026) create legal and sentiment risk that can pressure the stock until resolved. Pomerantz PR Newswire notice Schall Law Firm notice

Insider Activity

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 10,029 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $228,661.20. Following the sale, the insider owned 110,026 shares in the company, valued at $2,508,592.80. This represents a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 8,409 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.70, for a total value of $190,884.30. Following the completion of the sale, the chief financial officer directly owned 86,669 shares of the company’s stock, valued at approximately $1,967,386.30. The trade was a 8.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.